References
- Giné E, Sehn LH. Diffuse large B-cell lymphoma: should limited-stage patients be treated differently? Hematol Oncol Clin North Am. 2016;30(6):1179–1194.
- Kumar A, Lunning MA, Zhang Z, et al. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2015;171(5):776–783.
- Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339(1):21–26.
- Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of southwest oncology group study S8736. J Cin Oncol. 2016;34(25):2997–3004.
- Lamy T, Damaj G, Gyan E, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams Group. Blood. 2014;124(21):393–393.
- Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281.
- Persky DO, Li H, Stephens DM, et al. Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-Cell Lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. DOI:10.1200/JCO.20.00999
- Cheah CY, Oki Y, Westin JR, et al. A clinician's guide to double hit lymphomas. Br J Haematol. 2015;168(6):784–795.
- Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cin Oncol. 2012;30(28):3452–3459.
- Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Cin Oncol. 2015;33(26):2848–2856.
- Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large b-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
- Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101.
- Provencio M, Royuela A, Torrente M, et al. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group. Cancer. 2017;123(19):3709–3716.
- Jakobsen LH, Bøgsted M, Brown PN, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Cin Oncol. 2017;35(7):778–784.